Injection pen market seen reaching $69.77B by 2031

Mordor Intelligence projects the global injection pen market will grow from $51.24 billion in 2026 to $69.77 billion by 2031 as diabetes care, self-administration and connected drug-delivery devices expand. North America remains the largest regional market, while Asia-Pacific is expected to grow the fastest.

Why it matters: - Injection pens are becoming a bigger part of chronic-care treatment as more patients self-administer injectable drugs at home. - Demand is rising across diabetes, obesity and other long-term conditions that rely on regular dosing. - Smart and connected pens are adding pressure on manufacturers to improve adherence tracking, dose monitoring and digital care integration.

What happened: - Mordor Intelligence estimated the global injection pen market at $51.24 billion in 2026. - The market is projected to reach $69.77 billion by 2031. - Mordor Intelligence expects the market to grow at a 6.37% CAGR from 2026 to 2031. - North America is the largest regional market, with a 35.98% share in 2025. - Asia-Pacific is projected to be the fastest-growing region, with an expected 11.35% CAGR during 2026–2031.

The details: - Rising diabetes prevalence is supporting demand for injection pens that let patients administer medication outside clinical settings. - Convenience is pushing adoption of pen-based delivery systems for long-term therapies that require regular dosing. - The expanding GLP-1 and GIP pipeline is increasing demand for injection pens used in diabetes and weight-management treatments. - Manufacturers are focusing on higher-capacity and adaptable delivery systems to support those therapies. - Smart and connected injection pens are gaining traction as healthcare systems emphasize adherence, dose tracking and connected care. - These devices can capture dosing information and support data sharing for digital health and remote patient management. - The market is segmented by product type into disposable, reusable and smart/connected pens. - The market is segmented by indication into diabetes, autoimmune diseases, growth hormone deficiency, oncology supportive care, osteoporosis and other indications. - The market is segmented by distribution channel into hospital pharmacies, retail pharmacies and online pharmacies. - The regional breakdown covers North America, Europe, Asia-Pacific, the Middle East and Africa, and South America. - In Europe, demand is supported by established healthcare systems, reusable delivery formats and sustainability priorities in medical-device manufacturing. - In Asia-Pacific, market growth is supported by rising diabetes prevalence, healthcare-system modernization, expanding insurance coverage and improving access to advanced drug-delivery technologies.

Between the lines: - The report points to a market shift from basic disposable delivery devices toward reusable and connected platforms. - That shift suggests competition will hinge less on simple device supply and more on usability, connectivity, manufacturing scale and regulatory execution. - The market is described as moderately concentrated, which means established players still have room to defend share through partnerships and product innovation. - Novo Nordisk’s recent Wegovy launches underscore how new obesity therapies can quickly create demand for specific pen formats.

What's next: - Novo Nordisk said it expected to launch Wegovy 7.2 mg in a single-dose pen in the EU in the third quarter of 2026 after a CHMP recommendation in May 2026. - Novo Nordisk launched Wegovy 7.2 mg single-dose pen in the United Kingdom in June 2026. - The company said rollout across the EU was planned for the second half of 2026. - Manufacturers are likely to keep emphasizing connected, reusable and therapy-specific pen designs as chronic-care demand expands. - The report is also available in Japanese, French, German, Spanish and Portuguese.

The bottom line: - The injection pen market is moving from a niche delivery category to a core platform for chronic disease treatment, led by diabetes, obesity care and digital-enabled self-administration. - More information is available in the full report.